Narrative review · PMID 41598480
Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss — VialBase Research
Tesamorelin is a GHRH agonist being explored for muscle preservation during weight loss
Last updated · 2026 · Multiple authors · Journal of Clinical Medicine
Key findings
- Tesamorelin is a GHRH agonist being explored for muscle preservation during weight loss
- Weight loss from GLP-1 RAs causes significant lean mass loss
- GHRH agonists, bimagrumab, and enobosarm target different preservation pathways
- Tesamorelin's FDA approval for lipodystrophy provides clinical safety data
PMID 41598480 — Lean Mass Preservation Pharmacology
Compound: Tesamorelin Citation: J Clin Med. 2026;15(2):541. doi:10.3390/jcm15020541
Summary
Reviews pharmacological strategies to preserve lean body mass during weight loss, a growing concern with widespread GLP-1 RA adoption. Tesamorelin is highlighted as a GHRH agonist with clinical safety data and potential for muscle preservation.
Relevance to Tesamorelin
Tesamorelin’s dual effect — visceral fat reduction + lean mass increase — makes it a rational candidate for combination with Liraglutide or Semaglutide to mitigate the muscle loss problem inherent to GLP-1 RA therapy. Among GHRH agonists, tesamorelin has the most robust clinical evidence (FDA-approved, multiple RCTs).
See Also
- Parent compound: Tesamorelin
- Sermorelin